Dr. Reddy’s (NYSE: RDY) files Q4 2025 unaudited results presentation

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited filed a Form 6-K as a foreign private issuer, providing an intimation dated January 21, 2026. The company has circulated a presentation on its unaudited financial results for the quarter ended December 31, 2025 to the National Stock Exchange of India, BSE, the New York Stock Exchange, and NSE IFSC.

The filing itself does not reproduce the financial figures, but formally records that these quarterly unaudited results have been prepared and shared with the stock exchanges for information and record purposes.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

January 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                   Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                       No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated January 21, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: January 21, 2026	By:	/s/ K Randhir Singh
		Name: K Randhir Singh
		Title: Company Secretary

3

Exhibit 99.1

  Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India   CIN: L85195TG1984PLC004507   Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com

January 21, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Q3 FY26 Unaudited Financial Results Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on the Unaudited Financial Results of the Company for the quarter ended December 31, 2025.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above

FAQ

What does Dr. Reddy’s Laboratories (RDY) report in this Form 6-K?

The Form 6-K records that Dr. Reddy’s Laboratories has circulated a presentation on its unaudited financial results for the quarter ended December 31, 2025, as an enclosure.

Which period do the enclosed unaudited financial results of RDY cover?

The enclosed presentation relates to the company’s unaudited financial results for the quarter ended December 31, 2025.

Which stock exchanges received Dr. Reddy’s January 21, 2026 intimation?

The intimation and presentation were sent to the National Stock Exchange of India Ltd., BSE Limited, the New York Stock Exchange Inc., and NSE IFSC Ltd..

Are detailed financial numbers included in this Dr. Reddy’s (RDY) Form 6-K text?

The text refers to a presentation on unaudited financial results as an enclosure, but the specific financial figures are not included in the provided content.

Who signed the Form 6-K for Dr. Reddy’s Laboratories?

The Form 6-K was signed on behalf of Dr. Reddy’s Laboratories by K Randhir Singh, who is the Company Secretary, Compliance Officer & Head-CSR.